Hologic (HOLX), a medical device manufacturer, has outperformed the S&P 500 and its industry, returning +6.3% over the past month. The company anticipates current quarter EPS of $1.10 (+8.9% YoY) and revenue of $1.03 billion (+4.6% YoY), with current fiscal year estimates also projecting growth, supported by largely positive earnings estimate revisions. Despite a Zacks Value Style Score of 'B' suggesting it trades at a discount to peers, Hologic holds a Zacks Rank #3 (Hold), indicating a near-term performance in line with the broader market.
Hologic, Inc. (HOLX) has demonstrated strong recent market performance, with its shares returning +6.3% over the past month, outpacing both the S&P 500 composite's +3.3% gain and the Zacks Medical - Instruments industry's +3.5% rise. This momentum is supported by positive near-term growth forecasts and a history of solid execution. Analysts project current quarter earnings of $1.10 per share, representing an 8.9% year-over-year increase, with consensus estimates having been revised upward by 1.1% in the last 30 days. Similarly, revenue is expected to grow 4.6% YoY to $1.03 billion for the quarter. The company has a consistent track record of exceeding expectations, having surpassed consensus EPS and revenue estimates in three of the last four quarters. Despite these positive indicators and a 'B' grade for value which suggests it is trading at a discount to its peers, the outlook contains mixed signals. While current fiscal year estimates show modest growth, the consensus EPS estimate for the next fiscal year has seen a minor negative revision of -0.5% over the past month. This nuance likely contributes to its Zacks Rank #3 (Hold), indicating an expectation of performance in line with the broader market rather than significant outperformance in the near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
